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The plasma lysophospholipid mediator sphingosine-1-phosphate (S1P) is produced 
exclusively by sphingosine kinase (SPHK) 1 and SPHK2 in vivo, and plays diverse 
biological and pathophysiological roles by acting largely through three members of the 
G protein-coupled S1P receptors, S1P1, S1P2 and S1P3. S1P1 expressed on endothelial 
cells mediates embryonic vascular maturation and maintains vascular integrity by 
contributing to eNOS activation, inhibiting vascular permeability and inducing 
endothelial cell chemotaxis via Gi-coupled mechanisms. By contrast, S1P2 is expressed 
in high levels on vascular smooth muscle cells (VSMCs) and certain types of tumor 
cells, inhibiting Rac and cell migration via a G12/13- and Rho-dependent mechanism. In 
rat neointimal VSMCs, S1P1 is upregulated to mediate local production of 
platelet-derived growth factor, which is a key player in vascular remodeling. S1P3 
expressed on endothelial cells also mediates chemotaxis toward S1P and vasorelaxation 
via NO production in certain vascular bed, playing protective roles for vascular integrity. 
S1P3 expressed on VSMCs and cardiac sinoatrial node cells mediates vasopressor and 
negative chronotropic effect, respectively. In addition, S1P3, together with S1P2 and 
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SPHK1, is suggested to play a protective role against acute myocardial ischemia. 
However, our recent work indicates that overexpressed SPHK1 is involved in 
cardiomyocyte degeneration and fibrosis in vivo, in part through S1P activation of the 
S1P3 signaling. We also demonstrated that exogenously administered S1P accelerates 
neovascularization and blood flow recovery in ischemic limbs, suggesting its usefulness 
for angiogenic therapy. These results provide evidence for S1P receptor subtype-specific 











  Sphingosine-1-phosphate (S1P) is a lysophospholipid mediator circulating in blood, 
which induces a wide variety of biological responses in a diversity of cell types [1-5]. 
These include stimulation of cell proliferation, inhibition of apoptosis and regulation of 
cell shape and cell motility, among others. S1P is present at the order of 10-7 M 
concentration in the plasma, largely in forms bound to plasma proteins including HDL 
and albumin [1]. S1P is generated by the phosphorylation of sphingosine by sphingosine 
kinases (SPHKs) 1 and 2, which share a conserved catalytic domain but are expressed in 
spaciotemporally distinct manners [6]. Deletion of either SPHK1 or SPHK2 is 
functionally fully compensated by the other isozyme, whereas SPHK1/SPHK2 double 
knockout mice are embryonic lethal, indicating that S1P is produced exclusively by 
SPHK’s in vivo. The major source of plasma S1P is believed to be red blood cells and 
activated platelets [1, 7], which lack S1P degrading enzyme S1P lyase. In addition, 
extracellular SPHK1, which is derived from vascular endothelial cells and other types of 
cells, also likely contributes to production of plasma S1P [8].  
  Identification of a family of G protein-coupled cell surface receptors specific for S1P 
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provided strong support for the notion that most, if not all, of the diversity of biological 
activities of S1P are mediated through either of the S1P receptors [2-5]. However, in 
lower organisms, which lack S1P receptors, and in certain biological events in 
mammalian cells S1P and its precursors likely play regulatory roles. Indeed, a recent 
study demonstrated that SPHK1KO mice show defective decidua formation and 
decidual angiogenesis in the SPHK2 heterozygous genetic background, without a 
reduction in S1P levels but with marked elevations in sphingosine levels and 
intracellular formation of abnormal membranous structures [9]. Intracellular 
accumulation of sphingosine is suggested to cause inhibition of polyp growth in 
SPHK1KO mice in murine genetic intestinal polyposis model, in which S1P levels were 
not different from wild type mice [10]. An intracellular role for S1P is suggested in mast 
cell activation [11].  
Among five S1P receptor subtypes S1P1-5, S1P1, S1P2 and S1P3 are widely expressed 
in various tissues [2-5], whereas S1P4 and S1P5 are expressed mainly in the immune 
system and the nervous system, respectively. The diversity of S1P actions depends upon 
their subtype-specific distinct repertoire of heterotrimeric G protein coupling, in 
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combination with tissue- and cell type-specific expression patterns (Fig. 1).  
   In this review, we focus on the cardiovascular system and angiogenesis, describing 
current knowledge on S1P actions and signaling mechanisms in this system, which 
includes novel actions of S1P that we recently identified. Understanding the 
cardiovascular actions of S1P provides insights into the pathophysiological roles and 
therapeutic significance of S1P in the cardiovascular system.  
 
 
2. S1P receptor activities and signaling in the cardiovascular system revealed from 
gene knockout studies 
   S1P1 is coupled exclusively via Gi to Ras-MAP kinase, phosphoinositide (PI) 
3-kinase-Akt pathway and phospholipase C pathway, whereas S1P2 and S1P3 are 
coupled to multiple G proteins, i.e. Gq, G12/13 and Gi to activate phospholipase C pathway 
and Rho pathway as well as the above mentioned Gi-dependent pathways [2-6].   
S1P1 is a major S1P receptor expressed on vascular endothelial cells, and is required 
for recruitment of mural cells and vascular maturation at the embryonic stage. Either 
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systemic disruption of S1P1 gene or endothelial cell-selective knockout of S1P1 resulted 
in embryonic lethality with a defect in vascular maturation (see below) [12], a 
phenotype similar to that in SPHK1/SPHK2 double KO mice [13] which essentially 
lack S1P, underscoring the importance of S1P1 in S1P actions during embryonic phase.  
In addition, both S1P1KO and SPHK1/SPHK2 double KO mice show defects in 
development of the nervous system. S1P1 is also suggested to be involved in the 
maintenance of vascular integrity after birth, which includes inhibition of vascular 
permeability and endothelial cell survival [16-18]. 
S1P1 receptors expressed on lymphocytes are responsible for their migration out of 
thymus and lymph nodes into the bloodstream, which is a crucial step in lymphocyte 
recirculation and thus immunity [14]. The immunosuppressant prodrug FTY720 is 
specifically phosphorylated by SPHK2 to become an active agonist for S1P1, however, 
upon engagement to phosphorylated form of FTY720 S1P1 undergoes rapid 
internalization and degradation through a ubiquitin-dependent process and thus strong 
downregulation of lymphocyte S1P1 receptor [15]. This FTY720 phosphate activity as a 
functional S1P1 antagonist leads to failure of lymphocyte egress from thymus and 
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peripheral lymphoid organs, and thus functional lymphopenia.  
S1P2 receptor is essential for morphogenesis of the heart in Zebrafish [19]. Although 
it is dispensable for murine cardiac development [20-22], S1P2 receptor is required for 
functional integrity of the central nervous system in the weaning age and maintenance 
of normal structure and function of the inner ear in the adulthood [21, 22]. The latter 
role of S1P2 appears to involve functional maintenance of the vasculature in the stria 
vascularis in the inner ear, in which S1P2–mediated vasoconstriction controls arterial 
perfusion appropriately.  
S1P1 and S1P3 are dominant S1P receptors expressed in vascular endothelial cells, 
whereas S1P2 appears to be expressed only in endothelial cells of certain vascular beds 
[23]. Activation of S1P2 on endothelial cell inhibits their migration and the formation of 
tube-like structures on Matrigel, most likely through mechanisms involving 
Rho-dependent inhibition of Rac and/or stimulation of the 3’-specific phosphoinositide 
phosphatase PTEN [23, 24]. In murine model of hypoxia-induced retinal angiogenesis, 
it is reported that S1P2 expressed on the endothelium in the retinal vessels exerts an 
inhibitory effect on angiogenesis in neonatal avascular area of the retina, whereas S1P2 
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expressed on vessels in vascular tuft invading vitreal body rather promotes pathological 
neo-angiogenesis, which leads to retinal hemorrhage and thus blindness [25]. The 
results suggest complex roles of S1P2 in the regulation of pathological angiogenesis. In 
addition, activation of S1P2 induces disruption of adherens junctions and resultantly 
vascular hyperpermeability [26]. 
S1P3 receptor is abundantly expressed on vascular endothelial and medial smooth 
muscle cells, as well as cardiomyocytes [27]. S1P3KO mice are phenotypically normal 
[28], however, S1P3 deletion abrogates a variety of S1P effects on the cardiovascular 
system. These include negative chronotropic and hypertensive effects after intravenous 
administration of S1P in vivo, constriction of basilar artery, and endothelium-dependent 
vasodilation [27, 29]. S1P3 mediates bradycardia through activation of inward rectifying 
G protein-activated potassium channels (GIRK1/GIRK4) via Gi in sinoatrial node cells 
[30], vasoconstriction through Gq–coupled Ca2+ mobilization and G12/13–coupled 
Rho-dependent myosin light chain phosphatase inhibition in vascular smooth muscle 
cells (VSMCs) of certain vascular bed [27], and activation of eNOS and nitric oxide 
production in vascular endothelial cells through Gi- and Akt-mediated phosphorylation 
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of eNOS in concert with a Gq-mediated, Ca2+/calmodulin-dependent activation process 
[31]. Being a constituent of plasma HDL, S1P is proposed to partially contribute to 
HDL-induced, NO-dependent vasorelaxation. However, S1P potently reduces 
myocardial perfusion in a manner dependent exclusively upon S1P3 [32], despite the fact 
that HDL increases it. S1P is also vasoconstrictive for various vascular beds including 
kidney, mesentery and brain [33]. These observations, together with hypertensive effects 
of S1P, suggest that direct constrictive effects of S1P on vascular smooth muscle may 
dominate its endothelium-dependent dilatory effect in many vascular beds. 
 
 
3. S1P2–mediated inhibition of vascular smooth muscle cell migration, a possible 
therapeutic strategy  
   Regulation of VSMC migration is a potential target of vascular medicine in the near 
future. Upon endothelial damage, medial VSMCs are induced to migrate into the intima, 
which, together with bone marrow-derived vascular progenitor cells recruited to the site 
of endothelial lesion, undergoes phenotypic conversion to neointimal cells to contribute 
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to the formation of vascular occlusive lesions, including atheroma and post-angioplasty 
restenosis. Migration of VSMCs is induced by chemoattractants such as platelet-derived 
growth factor (PDGF) [34].  Chemoattractants induce chemotaxis, which is a directed 
cell migration toward an increasing concentration of chemoattractant. In such an 
environment polarized stimulation of the chemoattractant receptors at the front of the 
cell that faces increasing concentration of the ligand induces polarized activation of PI 
3-kinase and the Rho family small GTPase Rac, resulting in directed cell movement 
[35]. Growth factor receptors and chemokine receptors thus mediate chemotaxis 
through activation of PI 3-kinase and Rac, at the site downstream of receptor tyrosine 
kinases and βγ subunit of Gi, respectively.  
PDGF, which is a potent chemoattractant for VSMCs and released from the intimal 
VSMCs [34], acts on its cognate receptor tyrosine kinase to induce receptor tyrosyl 
auto-phosphorylation, followed by activation of PI 3-kinase and Rac, all of which are 
essential for a chemotactic response [17, 35]. S1P stimulation of S1P2 abolishes 
PDGF-directed chemotaxis. S1P2 activation also abolishes Rac activation and 
Rac-dependent actin re-organization, without inhibiting PDGF receptor 
 12 
autophosphorylation or PI 3-kinase stimulation [2, 17, 36]. Thus, inhibition of Rac 
activation is very likely a major mechanism for S1P2-mediated inhibition of cell 
migration. S1P2 by itself mediates Rho activation. Since botulinum C3 toxin, which 
inhibits Rho, abolishes inhibitory regulation of S1P2 it is likely that Rho activation is 
involved in S1P inhibition of Rac activity in VSMCs (S. Takashima et al., unpublished 
observation).  
   We analyzed in detail the G protein responsible for coupling S1P2 to inhibition of 
Rac and cell migration by studying the effects of expression of molecular probes, which 
include C-terminal mini-peptides of the heterotrimeric G protein α-subunits (Gα-CTs), 
which specifically inhibit receptor-Gα protein interaction, as well as βArk-CT, which 
acts as a scavenger for βγ [37]. The results indicate that, among three classes of the 
heterotrimeric G proteins G12/13, Gq and Gi that S1P2 activates [38], S1P2-mediated 
inhibition of Rac and cell migration requires both G12/13 and Gq (S. Takashima et al., 
unpublished observation). The G12/13 class induces Rho activation by direct physical and 
functional interaction between Gα12/13 and a group of Rho-guanine nucleotide exchange 
factors (Rho-GEFs), which includes p115RhoGEF, PDZ-RhoGEF and LARG [39], at 
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their conserved structural motif known as the regulator of G protein signaling domain 
(the RGS box). Gq was previously demonstrated to mediate Rho stimulation through 
mechanisms involving direct association of Gαq with Rho-GEFs in certain non-smooth 
muscle cell types. In VSMCs AT1 angiotensin II receptor couples to Gq to induce robust 
phospholipase C activation, however, AT1 by itself does not mediate either Rho 
stimulation or Rac inhibition (S. Takashima et al., unpublished observation). 
Phospholipase C or its downstream second messengers Ca2+ or protein kinase C are not 
likely to be involved in S1P2-mediated Rho activation in VSMCs either. The 
observations indicate that Gq activation by itself is not sufficient for effective Rho 
activation required for inhibition of Rac and migration in VSMCs. It is unknown 
whether this is due to lack of the expression in VSMCs of a Rho-GEF type that Gq can 
associate with, or due to alternative mechanisms. It is likely that Gq exerts a permissive 
effect on Rho activation in cooperation with G12/13.  
  There are several GPCR agonists that inhibit VSMC motility through Gs-coupled 
receptors and elevation in cellular cyclic AMP. These include prostaglandin E2 (PGE2), 
dopamine and adrenomedullin [40]. Different from these Gs-coupled receptors, which 
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suppress VSMC cell migration in the absence of a concentration gradient of the ligand 
[40], S1P2 mediates inhibition of cell migration only in the presence of S1P 
concentration gradient [36]. This property of S1P is a hallmark of a chemorepellant. 
Certain bioactive factors including the semaphorine and the ephrine family members 
have recently been defined as chemorepellants for neuronal and vascular cells. These 
molecules act as ligands for cell surface receptors that are distinct from GPCRs. S1P2 is 
the first example of a chemorepellant GPCR with an inhibitory activity for Rac [2]. 
   Sanchez et al. [26] showed that S1P2 inhibition of cell migration is mediated through 
stimulation of the 3’-specific PI phosphatase, PTEN, and in a Rho kinase-dependent 
manner. They suggested that PTEN stimulation by S1P2 may be responsible for 
inhibition of cell migration, because 3’-PIs participate in cell migration through 
multitudes of mechanisms including actin cytoskeletal re-organization, the protein 
kinase Akt activation, and Rac-GEF activation. However, we observed in VSMCs that 
knockdown of PTEN expression by RNAi did not affect S1P2–mediated inhibition of 
cell migration although PTEN knockdown effectively suppressed Akt activation 
(Sugimoto N et al., unpublished observations). The observations suggest that S1P2 
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mediates stimulation of PTEN in VSMCs as well, but that stimulation of PTEN does not 
mediate inhibition of VSMC migration. These observations may suggest that 
S1P2-mediated inhibition of cell migration depends upon different subcellular 
mechanisms among cell types. 
   A number of growth factors, hormones and cytokines have been implicated in the 
process of vascular restenosis, including PDGF, fibroblast growth factor (FGF), 
angiotensin II and transforming growth factor-β. Inhibitors of these receptors and 
downstream signaling pathways have been demonstrated to successfully inhibit stenosis 
in animal models. Among these, rapamycin, an inhibitor of mTOR which is a protein 
kinase located downstream of the PI 3-kinase signaling pathway, is proven to be 
effective in diminishing restenosis in patients when rapamycin-coated stents are 
implanted at stenotic sites. Selective activation of S1P2 receptor in VSMCs induces 
inhibition of the intracellular signaling molecules Rac and Akt, leading to inhibition of 
VSMC migration. Inhibition of Rac and Akt may also lead to anti-proliferation and 
apoptosis of VSMCs. If a selective S1P2 antagonist is locally administered at stenotic 
sites as a drug-eluting stent, it could inhibit accumulation of VSMCs into the luminal 
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surface by uniquely acting as both a chemorepellent and anti-proliferative agent, 
exerting a protective effect against vascular restenosis.  
 
 
4. In vivo angiogenic activity of S1P and its application for angiogenic therapy in 
tissue ischemia  
   The stimulatory activities of S1P in endothelial cell proliferation, migration and 
capillary-like tube formation in vitro are mediated via S1P1 and S1P3 and are reported to 
be as potent as well characterized angiogenic peptide growth factors including vascular 
endothelial growth factor (VEGF) and FGF-2 [16]. S1P also stimulates angiogenesis in 
vivo via S1P1 and S1P3 in the Matrigel implant assay [16]. Disruption of either S1P1 
gene or both SPHK1 and SPHK2 genes in mice demonstrated that S1P and its receptor 
S1P1 in vascular endothelial cells are essentially required for the recruitment process of 
pericytes and smooth muscle cells to the nascent capillaries and thus vascular 
maturation [12, 13]. A recent investigation [41] demonstrated that RNAi-mediated S1P1 
silencing inhibited tumor angiogenesis and tumor growth in vivo in an animal model of 
subcutaneous tumor implantation, indicating that endogenous S1P is involved in tumor 
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angiogenesis via S1P1. It is also reported that anti-S1P antibody potently reduced tumor 
growth [42]. Indeed, S1P stimulates barrier integrity of endothelial cells in vitro in part 
via S1P1-mediated upregulation of VE-cadherin and stimulation of intercellular 
adhesion [18, 44]. In vivo, S1P and the S1P receptor agonist FTY720-phosphate acutely 
suppress pulmonary edema and VEGF-induced vascular hyperpermeability [45]. In 
contrast, S1P2 and S1P3 disrupt endothelial integrity in vitro and increase vascular 
permeability in vivo [45, 46]. S1P2 expressed in endothelial cells also potently inhibits 
endothelial cell migration and capillary-like tube formation [17, 23]. These observations 
may suggest that selective S1P1 activation in combination with S1P2 activation should be 
a most promising strategy as an angiogenic treatment. 
In the light of high morbidity and mortality due to ischemic cardiovascular diseases 
in the developed countries, stimulating revascularization in underperfused tissues is an 
attractive novel therapeutic strategy [47]. To date, however, the results of clinical 
studies on topical and systemic administration of the angiogenic peptide growth factors, 
including VEGF, FGF-2 and hepatocyte growth factor, and their expression plasmids, 
have not been very satisfactory.  
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   The mouse hindlimb ischemic model is one of the well-established animal models 
for ischemia-induced angiogenesis in vivo to evaluate the potential of angiogenic factors 
as a therapeutic agent. We recently showed for the first time that S1P is useful in 
stimulating angiogenesis in vivo in the mouse hindlimb afte ischemia [48]. The ligation 
and removal of unilateral femoral artery induces a 95 % reduction in the blood flow as 
compared to the contralateral non-ischemic limb the day after operation (day 1), as 
evaluated with a laser Doppler blood flow analyzer. The blood flow thereafter gradually 
recovers over 4 weeks. Daily intramuscular administration of S1P in hindlimb muscle 
dose-dependently accelerates blood flow recovery, resulting in up to twice as much 
blood flow at days 7 and 14 as compared to vehicle control. The stimulatory effect on 
the blood flow by the optimal dose of S1P is similar in the magnitude as that induced by 
the potent angiogenic peptide growth factor FGF-2, providing ecidence that in vivo 
angiogenic strength of S1P is comparable to that of the known angiogenic factors. 
S1P-induced stimulation of the blood flow recovery is accompanied by an increase in 
the capillary density in the ischemic hindlimb muscle, suggesting that S1P-induced 
stimulation of blood flow recovery is due to neovessel formation. We recently generated 
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SPHK1-transgenic (SPHK1-Tg) mice (see below), which exhibits a marked increase in 
SPHK activity and a moderate increase in the S1P level in limb muscle as well as in 
other tissues. In SPHK1-Tg mice, the post-ischemic blood flow recovery and 
angiogenesis are accelerated as compared to WT littermates. One of the drawbacks in 
previous trials of angiogenic therapy is local tissue edema due to vascular leakage [47]. 
Daily S1P injection in wild type mice does not induce an increase in vascular leakage 
nor does SPHK1-Tg mice exhibit an increased vascular permeability in the ischemic 
limb, indicating that S1P-induced neo-angiogenesis is not accompanied by vascular 
hyperpermeability. S1P organizes endothelial tight junctions and adherens junctions 
[49] and promotes vascular mural cell recruitment at least in part via upregulation of 
N-cadherin [12, 50]. These effects of S1P likely lead to the protection of the neovessels 
from hyperpermeability. Daily local administration of S1P exhibits no adverse effect in 
mice, in terms of general conditions, the blood cell count or the cardiovascular 
parameters including the heart rate and blood pressure. These data collectively suggest 
potential usefulness of S1P or S1P1 agonist for therapeutic angiogenesis in ischemic 
conditions.  
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    Recent studies showed the contribution of bone marrow-derived circulating 
endothelial precursor cells to the new blood vessel formation in ischemic tissues. CD34+ 
vascular endothelial progenitors express S1P3 receptor [51]. Stimulation of progenitor 
S1P3 receptor with S1P or synthetic analog FTY720 activates the CXCR4 chemokine 
receptor which is essential for the effectiveness of progenitor cell therapy for 
angiogenesis. Therefore, S1P may stimulate angiogenesis not only by directly 
stimulating pre-existing endothelial cells but also through recruitment of circulating 
endothelial precursor cells.  
 
 
5. S1P and cardiac remodeling 
   Cardiomyocytes express S1P1, S1P2 and S1P3 [27]. S1P induces hypertrophy of 
cardiomyocytes in vitro via S1P1 [52]. In addition, all of the three major S1P receptor 
subtypes are also expressed in cardiac fibroblasts which participate in cardiac 
hypertrophy and fibrosis, i.e. cardiac remodeling [53]. S1P reduces mortality of hypoxic 
cardiac myocytes in vitro [54]. S1P is also playing protective roles for myocardial 
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ischemia. For example, in an in vivo mouse model of myocardial ischemia/reperfusion 
(IR), exogenous HDL and its lipid component S1P attenuated infarct size dramatically 
[55]. These effects of HDL and S1P were completely absent in S1P3KO mice. Deletion 
of both S1P2 and S1P3 receptors, but not either alone, in mice resulted in aggravation of 
acute myocardial infarction after experimental coronary artery ligation [56]. It is also 
reported, however, S1P potently reduces coronary perfusion [32], possibly via coronary 
arftery smooth muscle contraction. SPHK1 has been shown to have protective effects 
against IR injury in the perfused heart, and is involved in the process of ischemic 
preconditioning, in which mild ischemic pretreatment alleviates the extent of infarction 
caused by the subsequent ischemic session [57].  
   The heart expresses two SPHK isoforms, SPHK1 and SPHK2. Recent studies have 
demonstrated for various types of cells that stimulation with extracellular signals further 
stimulates cellular SPHK1 activity over the basal constitutive level. These include 
PDGF, nerve growth factor, muscarinic acetylcholine agonists, tumor necrosis factor-α, 
interleukin-1 and crosslinking of cell surface FcεRI or FcγRI, raising the possibility that 
SPHK1 and S1P are involved in certain pathological conditions. Indeed, Deutschman et 
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al. have reported that serum S1P level is the most reliable marker that predicts 
cardiovascular events to occur [58]. Overexpression of SPHK1 in cultures cells 
stimulates cell proliferation with accerelated G1 to S phase cell cycle progression, and 
in NIH3T 3 cells it resulted in cell transformation, leading to the notion that wild type 
SPHK1 gene is an oncogene [59]. 
   We have generated SPHK1a-Tg mice to evaluate the effect of SPHK1a 
overexpression in vivo (N. Takuwa et al., unpublished observations). The TG mice 
overexpress functional SPHK1a in diverse tissues with more than 10-fold increases in 
the enzymatic activity. However, the TG mice of both sexes were born without 
malformation, showed normal development with growth curves identical to those of WT 
littermates, and were fertile, indicating that SPHK1a overexpression does not 
compromise regulated cell proliferation, differentiation or apoptosis that are required for 
development and reproduction. The lifespan of the TG mice are not shorter than the WT 
littermates. Unexpectedly, we found that the SPHK1a-Tg mice exhibited degenerative 
changes in cardiomyocytes and myocardial fibrosis, which aggravated with age. The 
SPHK1a-Tg mouse heart showed a slight but significant increase in the cardiac S1P 
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content, but normal sphingosine and ceramide levels. Immunohistochemical analysis of 
SPHK1a in the TG heart tissue revealed SPHK1a overexpression in the myocardium.  
   The SPHK1a-Tg mice were normotensive and have normal blood cholesterol and 
glucose levels. Coronary blood vessels in the Tg mice were normal. These observations 
indicated that cardiac fibrosis in the Tg heart is not secondary to hypertension, ischemic 
heart disease or other metabolic disorders. Accumulated evidence in recent investigation 
suggests the involvement of the Rho family GTPases, particularly Rac and Rho, in 
cardiac remodeling including hypertrophy and fibrosis in mice and human [60]. S1P 
receptor signaling induces either activation or inhibition of Rac and activation of Rho, 
depending on the receptor subtype [35]. We observed activation of Rac and Rho in the 
Tg heart as compared to WT littermates. Long term administration of an HMG CoA 
reductase inhibitor pitavastatin, which inhibits geranylgeranylation and thus membrane 
targeting of both Rac and Rho [60], strongly inhibited the development of cardiac 
fibrosis, consistent with the notion that the Rho family GTPases are involved in the 
pathogenesis of cardiac fibrosis in SPHK1a-Tg mice. Development of cardiac fibrosis is 
strongly suppressed in S1P3KO mice, indicating that S1P3 is involved in cardiac fibrosis 
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in the SPHK1a-Tg mice. These observations show that transgenic overexpression of 
SPHK1a in the mouse heart tissue leads to progressive cardiomyocyte degeneration and 
cardiac fibrosis, which likely involves activation of the S1P3-Rho family small G 
protein signaling pathway as a mechanism. The relevance of these observations in 
transgenic mice to human cardiac fibrosis of the ischemic, hypertensive and other 




   Recent investigation has revealed an ever increasing list of previously unrecognized 
important roles for the S1P signaling system in homeostasis and pathophysiology of the 
cardiovascular system (Fig. 1). These include embryonic vascular maturation, regulation 
of angiogenesis and vascular integrity, vascular contraction and NO-mediated relaxation, 
autoregulation of vascular tone and the heart rate, as well as roles for coronary perfusion, 
ischemic preconditioning, protection against ischemia and myocardial remodeling. 
Modulation of the S1P signaling system by targeting S1P receptors and 
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sphingolipid-metabolizing enzymes, including SPHK1 and possibly other members, are 
expected to provide new therapeutic modalities for cardiovascular diseases, such as 
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Figure 1. S1P signaling and actions through S1P1, S1P2 and S1P3 receptors in the 
cardiovascular system. S1P, which is synthesized by membrane sphingolipid 
metabolism and final phosphorylation of sphingosine by SPHKs, binds to S1P1, S1P2 
and S1P3 in vascular endothelial cells, VSMCs, and cardiomyocytes. These three 
receptors activate partially overlapping but distinct sets of signaling pathways, to exert 
complex effects on cardiovascular cells, which include stimulation or inhibition of cell 
migration and angiogenesis, a decrease or increase in vascular permeability, vascular 
contraction or relaxation, and protection from myocardial ischemia. SPP, 
sphingosine-1-phosphate phosphatase; SPL, sphingosine-1-phosphate lyase; VSM, 




















Decrease in vascular permeability Inhibition of migrationInhibition of angiogenesis
Increase in vascular permeability
VSM contraction
Bradycardia 
Myocardial protection from hypoxic 
damage
Increase in vascular permeability 
VSM contraction Fig. 1
